Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-28T03:08:19.821Z Has data issue: false hasContentIssue false
  • English
  • Français

Evolution of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence among employees of a US academic children’s hospital during coronavirus disease 2019 (COVID-19) pandemic

Part of: SARS-CoV-2/COVID-19

Published online by Cambridge University Press:  02 December 2021

Brian T. Fisher Open the ORCID record for Brian T. Fisher [Opens in a new window] ,
Anna Sharova ,
Craig L. K. Boge ,
Sigrid Gouma Open the ORCID record for Sigrid Gouma [Opens in a new window] ,
Audrey Kamrin ,
Jesse Blumenstock ,
Sydney Shuster Open the ORCID record for Sydney Shuster [Opens in a new window] ,
Lauren Gianchetti ,
Danielle Collins Open the ORCID record for Danielle Collins [Opens in a new window]  and
Elikplim Akaho
...Show all authors
Brian T. Fisher*
Affiliation:
Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Anna Sharova
Affiliation:
Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Craig L. K. Boge
Affiliation:
Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Sigrid Gouma
Affiliation:
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Audrey Kamrin
Affiliation:
Center for Human Phenomic Science, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Jesse Blumenstock
Affiliation:
Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Sydney Shuster
Affiliation:
Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Lauren Gianchetti
Affiliation:
Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Danielle Collins
Affiliation:
Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Elikplim Akaho
Affiliation:
Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
Madison E. Weirick
Affiliation:
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Christopher M. McAllister
Affiliation:
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Marcus J. Bolton
Affiliation:
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Claudia P. Arevalo
Affiliation:
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Eileen C. Goodwin
Affiliation:
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Elizabeth M. Anderson
Affiliation:
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Shannon R. Christensen
Affiliation:
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Fran Balamuth
Affiliation:
Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Audrey R. Odom John
Affiliation:
Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Yun Li
Affiliation:
Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Susan Coffin
Affiliation:
Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Jeffrey S. Gerber
Affiliation:
Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
Scott E. Hensley
Affiliation:
Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
*
Author for correspondence: Brian T. Fisher, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

To describe the cumulative seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies during the coronavirus disease 2019 (COVID-19) pandemic among employees of a large pediatric healthcare system.

Design, setting, and participants:

Prospective observational cohort study open to adult employees at the Children’s Hospital of Philadelphia, conducted April 20–December 17, 2020.

Methods:

Employees were recruited starting with high-risk exposure groups, utilizing e-mails, flyers, and announcements at virtual town hall meetings. At baseline, 1 month, 2 months, and 6 months, participants reported occupational and community exposures and gave a blood sample for SARS-CoV-2 antibody measurement by enzyme-linked immunosorbent assays (ELISAs). A post hoc Cox proportional hazards regression model was performed to identify factors associated with increased risk for seropositivity.

Results:

In total, 1,740 employees were enrolled. At 6 months, the cumulative seroprevalence was 5.3%, which was below estimated community point seroprevalence. Seroprevalence was 5.8% among employees who provided direct care and was 3.4% among employees who did not perform direct patient care. Most participants who were seropositive at baseline remained positive at follow-up assessments. In a post hoc analysis, direct patient care (hazard ratio [HR], 1.95; 95% confidence interval [CI], 1.03–3.68), Black race (HR, 2.70; 95% CI, 1.24–5.87), and exposure to a confirmed case in a nonhealthcare setting (HR, 4.32; 95% CI, 2.71–6.88) were associated with statistically significant increased risk for seropositivity.

Conclusions:

Employee SARS-CoV-2 seroprevalence rates remained below the point-prevalence rates of the surrounding community. Provision of direct patient care, Black race, and exposure to a confirmed case in a nonhealthcare setting conferred increased risk. These data can inform occupational protection measures to maximize protection of employees within the workplace during future COVID-19 waves or other epidemics.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 43 , Issue 11 , November 2022 , pp. 1647 - 1655
Check for updates
Copyright
© The Author(s), 2021. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Sikkema, RS, Pas, SD, Nieuwenhuijse, DF, et al. COVID-19 in healthcare workers in three hospitals in the south of the Netherlands: a cross-sectional study. Lancet Infect Dis 2020;20:1273–1280.CrossRefGoogle ScholarPubMed
Moscola, J, Sembajwe, G, Jarrett, M, et al. Prevalence of SARS-CoV-2 antibodies in healthcare personnel in the New York City area. JAMA 2020;324:893–895.CrossRefGoogle Scholar
Behrens, GMN, Cossmann, A, Stankov, MV, et al. Perceived versus proven SARS-CoV-2-specific immune responses in healthcare professionals. Infection 2020;48:631–634.CrossRefGoogle Scholar
Dacosta-Urbieta, A, Rivero-Calle, I, Pardo-Seco, J, et al. Seroprevalence of SARS-CoV-2 among pediatric healthcare workers in Spain. Front Pediatr 2020;8:547.CrossRefGoogle ScholarPubMed
Goldblatt, D, Johnson, M, Falup-Pecurariu, O, et al. Cross-sectional prevalence of SARS-CoV-2 antibodies in healthcare workers in paediatric facilities in eight countries. J Hosp Infect 2021;110:60–66.CrossRefGoogle ScholarPubMed
Harris, PA, Taylor, R, Thielke, R, Payne, J, Gonzalez, N, Conde, JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–381.CrossRefGoogle ScholarPubMed
Harris, PA, Taylor, R, Minor, BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019;95:103208.CrossRefGoogle ScholarPubMed
Sikkens, JJ, Buis, DTP, Peters, EJG, et al. Serologic surveillance and phylogenetic analysis of SARS-CoV-2 infection among hospital healthcare workers. JAMA Netw Open 2021;4:e2118554.CrossRefGoogle Scholar
Flannery, DD, Gouma, S, Dhudasia, MB, et al. SARS-CoV-2 seroprevalence among parturient women in Philadelphia. Sci Immunol 2020;5.Google ScholarPubMed
Stokes, EK, Zambrano, LD, Anderson, KN, et al. Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020. Morb Mortal Wkly Rep 2020;69:759–765.CrossRefGoogle ScholarPubMed
Otto, WR, Geoghegan, S, Posch, LC, et al. The epidemiology of severe acute respiratory syndrome coronavirus 2 in a pediatric healthcare network in the United States. J Pediatric Infect Dis Soc 2020;9:523–529.CrossRefGoogle Scholar
Akinbami, LJ, Vuong, N, Petersen, LR, et al. SARS-CoV-2 seroprevalence among healthcare, first response, and public safety personnel, Detroit metropolitan area, Michigan, USA, May–June 2020. Emerg Infect Dis 2020;26:2863–2871.CrossRefGoogle Scholar
Lopez, L, Hart, LH, Katz, MH. Racial and ethnic health disparities related to COVID-19. JAMA 2021;325:719–720.CrossRefGoogle ScholarPubMed
Seow, J, Graham, C, Merrick, B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 2020;5:1598–1607.CrossRefGoogle ScholarPubMed
Wajnberg, A, Amanat, F, Firpo, A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 2020;370:1227–1230.Google ScholarPubMed
Dan, JM, Mateus, J, Kato, Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021;371.Google ScholarPubMed